An Observational Study of First-Line Capecitabine Based Chemotherapy in Participants With Metastatic Colorectal Cancer (AXEL)
Program for Assessment of Capecitabine (Xeloda) Based First-line Therapies in Metastatic Colorectal Cancer (AXEL Study)
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Budapest, Hungría, 1145
- Fövárosi Önkormányzat uzsoki utcai Kórház
-
Budapest, Hungría, 1088
- Semmelweis Egyetem, II. Belgyogyaszati Klinika
-
Budapest, Hungría, 1125
- Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika
-
Budapest, Hungría, 1032
- Szent Margit Hospital
-
Budapest, Hungría, 1076
- Fov.Onk.Peterfy S.Utcai Korh.-Rend.Int es Baleseti Kozp.
-
Debrecen, Hungría, 4031
- Kenezy Korhaz Rendelointezet
-
Gyor, Hungría, 9024
- Petz Aladar Megyei Oktato Korhaz
-
Gyula, Hungría, 5700
- Békés Megyei Pándy Kálmán Kórház; Onkologiai tanszek
-
Kecskemet, Hungría, 6000
- Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont
-
Kistarcsa, Hungría, 2143
- Pest Megyei Flor Korhaz; Oncology
-
Miskolc, Hungría, 3501
- Borsod-Abauj-Zemplen Megyei Korhaz Es Egyetemi Oktato Korhaz; Onkologiai Osztaly
-
Nyíregyháza, Hungría, 4400
- Josa Andras Korhaz; Dept of Oncoradiology
-
Pecs, Hungría, 7623
- Pécsi Tudományegyetem Áok; Onkoterapias Intezet
-
Salgótarján, Hungría, 3100
- Szent Lázár Kórház
-
Szeged, Hungría, 6720
- Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika
-
Szekesfehervar, Hungría, 8000
- Szent Gyorgy Korhaz;Fejer Megyei
-
Szekszard, Hungría, 7100
- Tolna Megyei Onkormanyzat Balassa Janos Korhaz
-
Szentes, Hungría, 6600
- Dr. Bugyi Istvan Korhaz
-
Szombathely, Hungría, 9700
- Vas Megyei Markusovszky Korhaz X; Oncoradiology
-
Tatabanuya, Hungría, 2800
- Szent Borbala Korhaz
-
Veszprem, Hungría, 8200
- Veszprem Megyei Csolnoky; Ferenc Korhaz
-
Zalaegerszeg, Hungría, 8900
- Zala megyei Önkormányzat Kórház és Rendelõintézet
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Participants with newly diagnosed mCRC who have started first-line capecitabine-based chemotherapy in accordance with the current Hungarian label
Exclusion Criteria:
- History of serious or unexpected reaction to fluoropyrimidine therapy
- Hypersensitivity to the active ingredient of Xeloda or to any of the excipients of the product, or to fluorouracil
- Known dihydropyrimidine dehydrogenase deficiency
- Pregnancy or lactation
- Inadequate bone marrow, hepatic or renal function
- Treatment with sorivudine or its chemical analogues (for example, brivudine)
- If any contraindication for any drug used in the combination treatment schedules is present, the drug in question cannot be used
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Metastatic Colorectal Carcinoma (mCRC) Participants
Newly diagnosed mCRC participants, who will receive first line capecitabine based chemotherapy according to effective official Summary of Product Characteristics, will be observed.
The choice of therapy is based exclusively on the medical decision of the treating physician before study enrollment.
The study protocol does not enforce treatment initiation and also do not specify any treatment regimen.
|
First line capecitabine based oral tablet treatment in line with the effective Summary of Product Characteristics
Otros nombres:
First line chemotherapy according to effective official Summary of Product Characteristics.
The study protocol does not specify any particular therapy.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Median Progression-free Survival (PFS)
Periodo de tiempo: Baseline until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurred first, evaluated up to Day 1254
|
PFS was assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and is defined as the time from the first dose of indicated treatment to disease progression (PD) or death, whichever occurred first.
Participants who did not progress or died while being followed were censored on the date of the last visit.
Participants without post-baseline tumor assessments were conservatively censored on the date of first study medication, which is PFS was assigned a value of 1 day.
PD: at least 20 percent (%) increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 millimeter (mm); progression of existing non-target lesions; or presence of new lesions.
Median PFS was estimated using Kaplan-Meier method.
|
Baseline until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurred first, evaluated up to Day 1254
|
|
PFS by Therapeutic Regimens
Periodo de tiempo: Baseline until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurred first, evaluated up to Day 1254
|
PFS was assessed using RECIST v1.1 and is defined as the time from the first dose of indicated treatment to PD or death, whichever occurred first.
Participants who did not progress or died while being followed were censored on the date of the last visit.
PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm; progression of existing non-target lesions; or presence of new lesions.
Median PFS was estimated using Kaplan-Meier method.
|
Baseline until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurred first, evaluated up to Day 1254
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of Participants With Overall Response as Assessed by Investigator Using RECIST v1.1
Periodo de tiempo: Baseline until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurred first, evaluated up to Day 1254
|
Overall response is defined as a complete response (CR) or a partial response (PR) as determined by the Investigator using RECIST v1.1 on 2 consecutive occasions at least 6 weeks apart.
Participants were evaluated for tumor response per RECIST v1.1 and assessed by computed tomography (CT) or magnetic resonance imaging (MRI):CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease.
All nodes, both target and non-target, must decrease to normal (short axis less than (<) 10 mm).
No new lesions.PR was defined as greater than or equal to (>=) 30% decrease under baseline of the sum of diameters of all target lesions.
The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions.
No unequivocal progression of non-target disease.
No new lesions.
|
Baseline until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurred first, evaluated up to Day 1254
|
|
Percentage of Participants With Clinical Benefit as Assessed Using RECIST v1.1
Periodo de tiempo: Baseline until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurred first, evaluated up to Day 1254
|
Clinical benefit was defined as having a confirmed CR, PR or stable disease (SD) for at least 24 weeks on study according to RECIST v1.1.CR: complete disappearance of all target lesions and non-target disease,with the exception of nodal disease.All nodes,both target and non-target, must decrease to normal (short axis <10 mm).No new lesions.PR: >=30% decrease under baseline of the sum of diameters of all target lesions.The short axis was used in the sum for target nodes,while the longest diameter was used in the sum for all other target lesions.No unequivocal progression of non-target disease.No new lesions.SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD,taking as reference the smallest sum diameters while on study.PD:at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions,or presence of new lesions.
|
Baseline until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurred first, evaluated up to Day 1254
|
|
Percentage of Participants Who Underwent Metastasectomy
Periodo de tiempo: Baseline up to 1254 days
|
Metastasectomy is the surgical removal of metastases, which are secondary cancerous growths that have spread from cancer originating in another organ in the body.
|
Baseline up to 1254 days
|
|
Mean Duration of Capecitabine Therapy
Periodo de tiempo: Baseline up to 1254 days
|
Baseline up to 1254 days
|
|
|
Percentage of Participants With Dose Modification of Capecitabine
Periodo de tiempo: Baseline up to 1254 days
|
Baseline up to 1254 days
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Neoplasias
- Neoplasias por sitio
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades Gastrointestinales
- Enfermedades del Colon
- Enfermedades intestinales
- Neoplasias Intestinales
- Enfermedades Rectales
- Neoplasias colorrectales
- Mecanismos moleculares de acción farmacológica
- Antimetabolitos, Antineoplásicos
- Antimetabolitos
- Agentes antineoplásicos
- Capecitabina
Otros números de identificación del estudio
Otros números de identificación del estudio
- ML27791
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .